Tue, 31 Jul 2018 11:06:00 +0100
PAREXEL Advances Patient-Centric Drug Development with Introduction of its Patient Innovation Center
BOSTON, September 11, 2018 – PAREXEL International Corporation, a leading innovator of global biopharmaceutical services, today announced the launch of its Patient Innovation Center, designed to help guide sponsors in their efforts to improve efficiency and success across all areas of biopharmaceutical development including clinical trial design, recruitment, execution and market access. With a patient-centric approach, the Center can help sponsors improve the drug development process by reducing the practical, financial and geographical barriers patients...
Wed, 21 Feb 2018 12:06:00 +0100
LANSA Raises Bar for Low-Code Software Development with New Release of Visual LANSA
London, UK - 31 July 2018 - LANSA (www.lansa.com), the original low-code vendor, has announced a major new release of its software development platform, Visual LANSA. This raises the enterprise app development bar by delivering the ability to build scalable mobile, web and desktop applications significantly faster than before.This latest release will accelerate customers’ digital transformation projects, from disruptive customer apps to critical line-of-business solutions. Visual LANSA developers now have access to a range of...
Mon, 12 Feb 2018 14:08:00 +0100
BD Launches Circulating Cell-Free DNA Blood Collection Tube for Cancer and Non-Invasive Prenatal Testing Applications
CE-IVD labeled PAXgene
Mon, 18 Dec 2017 15:16:00 +0100
PAREXEL Introduces Biological Sample Lifecycle Management Service to Address Growing Demand Across Drug Development
Solution combines global laboratory logistics expertise with leading sample tracking software to optimize the management and care of human biological samples throughout their lifecycleBOSTON, February 12, 2018 – PAREXEL International Corporation, the world’s leading innovator of biopharmaceutical services, today launched its Biological Sample Lifecycle Management service, enabling optimal use of human biological samples. The new service enables biopharmaceutical clients to more efficiently manage their often irreplaceable patient biological sample assets from informed consent and collection...
Tue, 12 Dec 2017 14:00:00 +0100
PAREXEL Announces Enhanced Global Data Operations Offering to Drive Efficiencies for Life Science Companies
Solution now features Clinical Metadata Repository to meet evolving data standards while providing seamless and more timely workflow for clients from data collection, through analysis to submissionBOSTON, December 18, 2017 – PAREXEL International Corporation, a leading global biopharmaceutical services provider, today introduced its enhanced Global Data Operations (GDO) solution, with augmented processes and expertise that further bolsters its world leading clinical data services, including data management, statistical programming and biostatistics. The enhanced offering is designed...
Wed, 15 Nov 2017 14:40:00 +0100
PAREXEL Launches Perceptive® Cloud for the Life Sciences Industry
Cloud Platform Built on Microsoft Azure Delivers PAREXEL’s Valued Informatics Solutions on a Global, Trusted Architecture; Represents the First Offering of PAREXEL and Microsoft Alliance BOSTON, December 12, 2017 – PAREXEL International Corporation, a leading global biopharmaceutical services organization, today introduced the Perceptive
Wed, 06 Sep 2017 14:00:00 +0100
PAREXEL Expands Global Regulatory Services with Addition of Senior Executives from FDA and Oncology Industry
New Appointments Enhance PAREXEL’s Leadership and Expertise in Bringing Commercially Viable, Reimbursable Products to MarketBOSTON, November 15, 2017 — PAREXEL, a leading global biopharmaceutical services provider, today announced the appointment of three former senior regulatory consulting executives from the U.S. Food and Drug Administration (FDA) and Oncology industry positions. The new hires are part of PAREXEL’s Global Integrated Product Development and Compliance team and will be focused on helping PAREXEL clients deliver commercially viable, reimbursable...
Tue, 29 Aug 2017 15:00:00 +0100
PAREXEL Launches Real-World Data Service Offering to Drive Value Demonstration of New Treatments
Integrated offering to be provided by new dedicated service group under PAREXEL
Mon, 21 Aug 2017 14:37:00 +0100
Peter Rose divulges ins and outs of new MDR at RAPS Regulatory Convergence 2017
Peter Rose will be discussing the intricacies of the new Medical Device Regulation and providing insight for businesses to ensure seamless compliance at this year’s RAPS Regulatory Convergence29 August 2017 – Peter Rose, Managing Director for Maetrics operations in Europe and industry leader will be speaking at the upcoming RAPS Regulatory Convergence in Washington DC about the new Medical Device Regulation (MDR) in Europe. The new regulation has consolidated two existing legal provisions and replaced...
Mon, 19 Jun 2017 13:28:00 +0100
PAREXEL and Osaka International Cancer Institute Form Alliance to Advance Clinical Research in Japan
Alliance to drive greater efficiencies across clinical trials in oncology and hematologyBOSTON and OSAKA, August 21, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, and Osaka International Cancer Institute today announced that they have formed an alliance to advance clinical development in Japan. The partnership will aim to drive greater efficiencies in support of patient recruitment for clinical trials in oncology and hematology, accelerating the development of innovative and effective...
Fri, 16 Jun 2017 12:48:00 +0100
PAREXEL introduces its Connected Journey™ of newly integrated data-driven services to simplify drug development and commercialisation
Features new ForeSite™ clinical trial methodology designed to reliably predict site successLONDON, June 19, 2017 – As life science companies increasingly seek to gain insights from diverse data sources to make drug development more efficient and effective, PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, is launching its Connected Journey™ of data-driven services. This newly integrated network, powered by PAREXEL
Thu, 15 Jun 2017 13:04:00 +0100
ZCube announces the second edition of Open Accelerator: an international call for ideas for life sciences startups
Milan, 16th June, 2017 – ZCube, Research Venture of the pharmaceutical group Zambon, launches the second edition of Open Accelerator, a fast track acceleration program for life science start-up projects.Open Accelerator is a 12-steps program providing training to international researchers, scientists and aspiring entrepreneurs that, following a selection process, could receive seed investment of up to €100.000 per project. Entries can be made following this link: http://www.openaccelerator.it/. The call for ideas will be open until...
Mon, 03 Apr 2017 14:25:00 +0100
PAREXEL Collaborates With Sanofi To Advance The Use Of Wearable Devices In Life Science Industry
Preliminary findings from pilot study validate use of wearable technologies to collect data and manage clinical trials more effectively and efficientlyLONDON, June 15, 2017 - PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organisation, today announced a collaboration with Sanofi to advance the use of wearable devices to transform the collection of data in clinical trials.Wearables have the potential to address several challenges related to clinical trials and improve execution by increasing patients’...
Mon, 13 Feb 2017 14:00:00 +0100
PAREXEL Ranked A Top CRO In CenterWatch Global Investigative Site Relationship Survey
Company recognised for sponsor/site relationship qualityLONDON, April 3, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organisation, today announced that it was named a top contract research organisation (CRO) in the CenterWatch 2017 Global Investigative Site Relationship Survey. The survey recognises CROs that have high-quality working relationships with investigative sites.The survey, published today in CenterWatch Monthly, polled over 1,300 global investigative sites on aspects of their relationships with CROs during the...
PAREXEL Launches ClinPhone RTSM Mobile App to Improve Supply Management and Increase Patient Safety
LONDON, February 13, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today launched a mobile app for the ClinPhone
view page: 80